Tag: Oberland Capital Healthcare
– Significantly Exceeds Target –
Oberland Capital, an investment firm focused on the global healthcare industry, announced today the closing of its inaugural royalty and credit opportunities fund, Oberland Capital Healthcare, with $425 million in capital commitments.
Oberland Capital provides healthcare companies, institutions and inventors customized financing solutions with an emphasis on the biopharmaceutical, medical device and diagnostic sectors. The fund targets investments ranging from $15 million to $100 million and has the ability to execute substantially larger transactions.
“We are grateful for the support shown by our limited partners in helping us to significantly surpass the $350 million target size for our first fund. The strong response from investors is a testament to the quality and experience of our investment team and the demand for non-correlated investment strategies. We look forward to building a diversified portfolio of attractive healthcare investments,” said Andrew Rubinstein, Managing Partner.
The development and commercialization of breakthrough medical technologies is highly capital intensive, creating a large market opportunity for Oberland Capital Healthcare. “Our flexible, long-term financing solutions provide an attractive source of capital to healthcare companies, institutions and inventors,” added Jean-Pierre Naegeli, Managing Partner. “We are excited to work with our transaction partners worldwide to enable them to meet their strategic and financial objectives.”
Investors in Oberland Capital Healthcare include public and corporate pension plans, financial institutions, foundations and endowments located throughout the United States and Europe.